In the news - Cerevel Therapeutics
Cerevel Therapeutics has a diversified pipeline comprising four clinical-stage investigational therapies and several pre-clinical compounds with the potential to treat a range of neuroscience diseases, including Parkinson’s, epilepsy, schizophrenia and substance use disorders.
Privacy Policy - Cerevel Therapeutics
Cerevel Therapeutics, Inc. and/or its affiliates (“Cerevel,” “we,” “us” or “our”) created and maintains the Cerevel website (the “Website”), currently located at cereveldev.wpengine.com, and other online services owned or controlled by Cerevel (collectively, the “Services”).
News & Announcements | Cerevel Therapeutics
Apr 18, 2024 · Cerevel is now part of AbbVie Together we will deliver science that takes us closer to meaningful change for people with neurological and psychiatric disorders.
Cerevel Therapeutics to Host Investor Webcast Moderated by Stifel
Dec 4, 2020 · Cerevel Therapeutics has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinson’s disease and …
Cerevel Therapeutics News Releases
CAMBRIDGE, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report third quarter 2023 financial results and business updates on Wednesday, November 1,
Early Access Program (EAP) Policy - Cerevel Therapeutics
Cerevel Therapeutics does not offer early access programs (EAP) for any of our investigational compounds. If you would like to learn more about our ongoing clinical studies please visit www.clinicaltrials.gov.
In the news - Cerevel Therapeutics
BOSTON – February 20, 2019 – Cerevel Therapeutics, a biopharmaceutical company focused on developing new medicines to treat disorders of the central nervous system (CNS), today announced that it has appointed veteran CNS medicines developer Raymond Sanchez, M.D. as chief medical officer.
In the news - Cerevel Therapeutics
BOSTON – September 14, 2020 – Cerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced Chairperson and Chief Executive Officer Tony Coles, M.D., will participate in a fireside chat at the Morgan Stanley 18th Annual Global Healthcare Conference on Wednesday, September 16 ...
Cerevel Therapeutics to Report Fourth Quarter 2021 Financial …
CAMBRIDGE, Mass., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report fourth quarter 2021 financial results on Tuesday, March 1, 2022, before the U.S. financial markets open.
Cerevel Therapeutics Announces the Appointment of Kathleen W.
Cerevel Therapeutics has a diversified pipeline comprising four clinical-stage investigational therapies and several pre-clinical compounds with the potential to treat a range of neuroscience diseases, including Parkinson’s, epilepsy, schizophrenia and substance use disorders.